Tamoxifen is widely used for the treatment of women diagnosed with certain types of early and advanced breast cancers, but not all patients will benefit from it. A team from Roswell Park Cancer Institute and Northwestern University examined the mechanisms behind tamoxifen resistance.

An accomplished urologic oncologist and longtime senior leader at Roswell Park Comprehensive Cancer Center was surprised with an incredible distinction at the National Comprehensive Cancer Network (NCCN) Annual Conference last week in Florida. James Mohler, MD, Associate Director and Senior Vice President for Translational Research, Chair of the Department of Urology, and Professor of Oncology at Roswell Park, received the 2017 Rodger Winn Award at the NCCN 22nd Annual Conference in Orlando, Fla.

More than 10 teams from Roswell Park Cancer Institute have been invited to present their research at the 70th Society of Surgical Oncology (SSO) Annual Cancer Symposium March 15-18 in Seattle, Washington, with two teams sharing their findings in oral abstract discussions.